ABBV's Newly Added Parkinson's Disease Drug Meets Second …
WEB2 hours ago · BVS. AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-1 study which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson ...
AbbVie Announces Positive Topline Results from Phase 3 TEMPO …
WEB14 hours ago · Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26; ... BioSpace is the digital hub for life science news and jobs. We provide …
News
WEB1 day ago · Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease. The TEMPO-1 trial evaluated the efficacy, safety and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy in adults with early Parkinson's disease.
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
WEB10 hours ago · AbbVie inherited tavapadon in August 2023 after it acquired Cerevel Therapeutics in an $8.7bn deal. The drug candidate is being evaluated in four clinical trials, dubbed TEMPO-1 to 4. These ...
AbbVie Announces Positive Topline Results from Phase 3 TEMPO …
WEB1 day ago · Tavapadon is a selective D1/D5 receptor partial agonist in development for Parkinson's disease and is currently being studied as a once-daily medicine for use as both a monotherapy and as an ...
Parkinson Agent Tavapadon Meets Primary and Secondary End …
WEB1 day ago · All told, tavapadon showed a safety profile that was consistent with previous observations, with a majority of the AEs being mild to moderate in severity. REFERENCES 1. AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease. …
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its …
WEB1 day ago · Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease. AbbVie added the drug candidate with its $8.7 billion ...
Abbvie drug improves Parkinson's symptoms in trial - STAT
WEB1 day ago · Annual. $399. Save 15%. Get Started. View All Plans. AbbVie's Parkinson’s drug, tavapadon, which it got from Cerevel Therapeutics, alleviated symptoms in a Phase 3 trial.
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase …
WEB1 day ago · (RTTNews) - Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease.
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon …
WEBApr 18, 2024 · Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks. Results demonstrate tavapadon’s potential to provide the right balance of motor control, safety and tolerability for ...